candesartan has been researched along with Hyperplasia in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of CV-11974, a potent nonpeptide antagonist of the angiotensin II (AII) type-1 receptor (AT1), on cytosolic free calcium concentration ([Ca2+]i), hyperplasia, and hypertrophy of cultured vascular smooth muscle cells (VSMC) from rat aorta were studied." | 7.69 | Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, and hypertrophy of cultured vascular smooth muscle cells. ( Fukuo, K; Inoue, T; Jiang, B; Koh, E; Morimoto, S; Nabata, T; Ogihara, T; Rakugi, H; Tomita, J, 1994) |
| "The effects of CV-11974, a potent nonpeptide antagonist of the angiotensin II (AII) type-1 receptor (AT1), on cytosolic free calcium concentration ([Ca2+]i), hyperplasia, and hypertrophy of cultured vascular smooth muscle cells (VSMC) from rat aorta were studied." | 3.69 | Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, and hypertrophy of cultured vascular smooth muscle cells. ( Fukuo, K; Inoue, T; Jiang, B; Koh, E; Morimoto, S; Nabata, T; Ogihara, T; Rakugi, H; Tomita, J, 1994) |
| "Candesartan treatment was associated with increased iNOS expression (p = ." | 2.84 | Support for involvement of the renin-angiotensin system in dysplastic Barrett's esophagus. ( Bratlie, SO; Casselbrant, A; Edebo, A; Fändriks, L, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bratlie, SO | 1 |
| Casselbrant, A | 1 |
| Edebo, A | 1 |
| Fändriks, L | 1 |
| Wakeyama, T | 1 |
| Ogawa, H | 1 |
| Iida, H | 1 |
| Takaki, A | 1 |
| Iwami, T | 1 |
| Mochizuki, M | 1 |
| Tanaka, T | 1 |
| Koh, E | 1 |
| Morimoto, S | 1 |
| Tomita, J | 1 |
| Rakugi, H | 1 |
| Jiang, B | 1 |
| Inoue, T | 1 |
| Nabata, T | 1 |
| Fukuo, K | 1 |
| Ogihara, T | 1 |
| Fukuda, N | 1 |
| Satoh, C | 1 |
| Hu, WY | 1 |
| Soma, M | 1 |
| Kubo, A | 1 |
| Kishioka, H | 1 |
| Watanabe, Y | 1 |
| Izumi, Y | 1 |
| Kanmatsuse, K | 1 |
2 trials available for candesartan and Hyperplasia
| Article | Year |
|---|---|
Support for involvement of the renin-angiotensin system in dysplastic Barrett's esophagus.
Topics: Adenocarcinoma; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2017 |
Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Benzimidazoles; Biphenyl Co | 2003 |
2 other studies available for candesartan and Hyperplasia
| Article | Year |
|---|---|
Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, and hypertrophy of cultured vascular smooth muscle cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Benzimidazoles; Biphenyl | 1994 |
Production of angiotensin II by homogeneous cultures of vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |